BioSpace News Archive

Eli Lilly and Company and Incyte announced initial data emerging from the Adaptive COVID-19 Treatment Trial sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

Company remains committed to working with FDA toward an approval for this important potential therapy

Meeting with the U.S. Food and Drug Administration (FDA) Planned for 4Q2020 to Discuss the Regulatory Path Forward for Zygel™ in Children and Adolescents with Fragile X Syndrome and a Fully Methylated FMR1 Gene

TransEnterix, Inc. announced that it established the first training center for the Senhance® Surgical System in the Asia-Pacific region in Japan at the Saitama Medical University International Medical Center in the Greater Tokyo Area.

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced the appointment of Natasha Giordano to its Board of Directors as an independent director and a member of the audit committee, effective Monday, September 14, 2020. Ms. Giordano brings over 25 years of extensive experience in healthcare, including senior leadership positions and board director roles spanning across several pharmaceutical companies and sales and marketin

INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today management will participate in Oppenheimer’s Fall Healthcare Life Science & Med Tech Virtual Investor Summit, on September 23, 2020. Management will be available for virtual one-on-one meetings during the conference. To schedule a meeting

Centene Corporation (NYSE: CNC) today announced it is working with Samsung Electronics America to expand access to telehealth for individuals living in rural and underserved communities. The initiative will supply providers with Samsung Galaxy A10e smartphones to disseminate to patients who would not otherwise have the ability to rec

Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced the appointment of David Hava, Ph.D. as Chief Scientific Officer.

Nevro Corp., a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced that it will establish global manufacturing operations in Costa Rica to invest in and support the Company’s future growth expectations.

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor for the treatment of myelofibrosis, today announced that Dr. Stephen Dilly , President and CEO, will present an overview of the company at two investor conference